Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 3, pp 703–712

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

  • Elisabeth I. Heath
  • George R. BlumenscheinJr
  • Roger B. Cohen
  • Patricia M. LoRusso
  • Noelle K. LoConte
  • Sindy T. Kim
  • Ana Ruiz-Garcia
  • Richard C. Chao
  • George Wilding
Original Article



To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin.


Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Schedule 2/1) or as a continuous daily dose for 3-week cycles (CDD schedule) in combination with paclitaxel (175–200 mg/m2) plus carboplatin (AUC 6 mg min/ml) on day one of each of 4 cycles. Dose-limiting toxicities (DLTs) and adverse events (AEs) were evaluated to determine the MTD. Efficacy parameters were analyzed in patients with measurable disease.


Forty-three patients were enrolled (n = 25 Schedule 2/1; n = 18 CDD schedule). Across all doses, 6 DLTs were observed [grade 4 papilledema, grade 5 GI hemorrhage, grade 3 neutropenic infection, and grade 4 thrombocytopenia (n = 3)]. The MTD for Schedule 2/1 was sunitinib 25 mg plus paclitaxel 175 mg/m2 and carboplatin AUC 6 mg min/ml. The MTD was not determined for the CDD schedule. Treatment-related AEs included neutropenia (77%), thrombocytopenia (56%), and fatigue (47%). Of 38 evaluable patients, 4 (11%) had partial responses and 12 (32%) had stable disease. PK data indicated an increase in maximum and total plasma exposures to sunitinib and its active metabolite when given with paclitaxel and carboplatin compared with sunitinib monotherapy.


Myelosuppression resulting in prolonged dose delays and frequent interruptions was observed, suggesting that this treatment combination is not feasible in the general cancer population.


Sunitinib Phase I Solid tumor NSCLC Antiangiogenesis Chemotherapy 


  1. 1.
    Keedy VL, Sandler AB (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98:1825–1830PubMedCrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: NSCLC v.2.2009. Available via
  3. 3.
    Khosravi SP, Fernandez PI (2008) Tumoral angiogenesis: review of the literature. Cancer Invest 26:104–108CrossRefGoogle Scholar
  4. 4.
    Tallquist M, Kazlauskas A (2004) PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15:205–213PubMedCrossRefGoogle Scholar
  5. 5.
    Saltz LB, Clarke S, az-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 20:2013–2019CrossRefGoogle Scholar
  6. 6.
    Robert NJ, Dieras V, Glaspy J et al (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27(15s):1005 AbstractGoogle Scholar
  7. 7.
    Nghiemphu PL, Liu W, Lee Y et al (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217–1222PubMedCrossRefGoogle Scholar
  8. 8.
    Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  9. 9.
    Homsi J, Daud AI (2007) Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14:285–294PubMedGoogle Scholar
  10. 10.
    Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295PubMedGoogle Scholar
  11. 11.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478PubMedGoogle Scholar
  12. 12.
    Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedGoogle Scholar
  13. 13.
    Motzer RJ, Hutson TE, Tomczak P et al (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24:2sGoogle Scholar
  14. 14.
    Motzer RJ, Figlin R, Hutson TE et al (2007) Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol ASCO Annual meeting proceedings part I. vol 25, no. 18S (20 June Suppl):(Abstract 5024)Google Scholar
  15. 15.
    Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRefGoogle Scholar
  16. 16.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  17. 17.
    Edgerly M, Fojo T (2008) Is there room for improvement in adverse event reporting in the era of targeted therapies? 1. J Natl Cancer Inst 100:240–242PubMedCrossRefGoogle Scholar
  18. 18.
    Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 Suppl 2: 16–23Google Scholar
  19. 19.
    Custodio Carretero AB, Garcia Saenz JA, Gonzalez Larriba JL et al (2008) Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clin Transl Oncol 10:560–571PubMedCrossRefGoogle Scholar
  20. 20.
    Perez EA (2004) Carboplatin in combination therapy for metastatic breast cancer. Oncologist 9:518–527PubMedCrossRefGoogle Scholar
  21. 21.
    Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810–1816PubMedCrossRefGoogle Scholar
  22. 22.
    Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650–656PubMedCrossRefGoogle Scholar
  23. 23.
    Kulke M, Lenz HJ, Meropol N et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410PubMedCrossRefGoogle Scholar
  24. 24.
    Kozloff M, Chuang E, Starr A et al (2010) An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 21:1436–1441Google Scholar
  25. 25.
    Robert F, Sandler A, Schiller JH et al (2010) Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 66:669–680PubMedCrossRefGoogle Scholar
  26. 26.
    Chiorean EG, Sweeney CJ, Verschraegen CF et al (2008) Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): a phase I dose-finding study. J Clin Oncol 26: 2008 (20 May suppl; abstract 3562)Google Scholar
  27. 27.
    Fountzilas G, Kalofonos HP, Dafni U et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic cooperative oncology group 1. Ann Oncol 15:1517–1526PubMedCrossRefGoogle Scholar
  28. 28.
    Karp DD, Novello S, Cardenal F et al (2009) Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 27 (15s) 8072: 15s (suppl; abstract)Google Scholar
  29. 29.
    Leong S, Cohen RB, Gustafson DL et al (2009) Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study 1. J Clin Oncol 27:4413–4421PubMedCrossRefGoogle Scholar
  30. 30.
    Pfizer Inc. (2008) Data on fileGoogle Scholar
  31. 31.
    Beulz-Riche D, Robert J, Riche C, Ratanasavanh D (2002) Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother Pharmacol 49:274–280PubMedCrossRefGoogle Scholar
  32. 32.
    Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brosen K (1999) In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289:31–37PubMedGoogle Scholar
  33. 33.
    Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78PubMedCrossRefGoogle Scholar
  34. 34.
    Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296:537–541PubMedGoogle Scholar
  35. 35.
    Baumhakel M, Kasel D, Rao-Schymanski RA et al (2001) Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 39:517–528PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Elisabeth I. Heath
    • 1
  • George R. BlumenscheinJr
    • 2
  • Roger B. Cohen
    • 3
  • Patricia M. LoRusso
    • 1
  • Noelle K. LoConte
    • 4
  • Sindy T. Kim
    • 5
  • Ana Ruiz-Garcia
    • 5
  • Richard C. Chao
    • 5
  • George Wilding
    • 4
  1. 1.Karmanos Cancer InstituteDetroitUSA
  2. 2.The University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Fox Chase Cancer CenterPhiladelphiaUSA
  4. 4.University of Wisconsin Carbone Cancer CenterMadisonUSA
  5. 5.Pfizer Oncology, Clinical DevelopmentSan DiegoUSA

Personalised recommendations